Skip to main content

Cellix Raises $1.4M in Second-Round Funding to Develop Cell-Based Screening Platform

NEW YORK (GenomeWeb News) – Cellix, a Dublin, Ireland-based developer of cell-based screening tools, said today that it has raised €1.1 million ($1.4 million) in second-round investment.
 
The company previously raised €800,000 in December 2006.
 
Cellix said that the new financing, provided by NCB Ventures of Ireland and OTC Asset Management of France, will enable it to accelerate development and commercialization of its Venaflux screening platform to address a range of therapeutic areas, including atherosclerosis, diabetes, oncology, and autoimmune disorders. 
 
VenaFlux measures cell adhesion to antibody-coated or endothelial-cell cultured microchannels in order to mimic human blood flow. The company said that it is seeing “significant growth” for the platform, which is currently in use at AstraZeneca, Pfizer, Sanofi-Aventis, and Servier.
 
Cellix will use the financing to support continued R&D “as well as further expansion into international markets.”

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.